VIDEO: MAJIC trial hopes to reveal best venetoclax-based doublet therapy in untreated CLL
In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed the randomized, phase 3 MAJIC trial, which he presented at ASH Annual Meeting and Exposition.
The trial-in-progress will compare acalabrutinib plus venetoclax vs. venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia. Davids and colleagues hope to determine the best venetoclax-based doublet therapy to use in the front-line CLL population.
“We’re hopeful that this will eventually answer a very important question in the field of CLL,” Davids said. “Interestingly, both of the regiments will be [measurable residual disease (MRD)]-guided in terms of the duration of therapy, so patients can receive either one or two years of treatment depending on how quickly they achieve undetectable MRD.”
Collapse
Davids, MS, et al. Abstract 1553. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Read more about